2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Non–Small Cell Lung Cancer
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC
MD Anderson Cancer Center
J Adv Pract Oncol 2019;10(6):576-583 |
© 2019 Harborside™
Options for patients with non–small cell lung cancer have expanded following trials studying the safety and efficacy of checkpoint inhibitors and targeted therapies. Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center reviews the major abstracts from the 2019 ASCO Annual Meeting using coverage by The ASCO Post and offers considerations for advanced practitioners in this field.
For access to the full length article, please sign in